文献速递焦虑、强迫与应激相关障碍

D-环丝氨酸增强暴露型认知行为疗法治疗焦虑、强迫及创伤后应激障碍:个体参与者数据系统综述与Meta分析

D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

该系统综述与Meta分析基于21项双盲随机对照试验的个体参与者数据(1047例),评估D-环丝氨酸(DCS)增强暴露型认知行为疗法对焦虑、强迫及创伤后应激障碍的效果。抗抑郁药未调节DCS效应,未发现预设调节因素与结局相关。

要点

  • DCS对暴露型CBT有小型增强效应,仅治疗后差异显著。
  • 抗抑郁药使用未调节DCS的增强效应。
  • 未识别出与DCS应答相关的患者或治疗特征。

核心结论

  • D-环丝氨酸对暴露型认知行为疗法有小型增强效应,且该效应不受抗抑郁药使用调节。

研究设计与样本

  • 系统综述与个体参与者数据Meta分析,纳入21项双盲随机对照试验,共1047例诊断为特定恐惧症、社交焦虑障碍、惊恐障碍伴或不伴广场恐惧症、强迫症或创伤后应激障碍的参与者。

主要发现

  • 分配至DCS的参与者在治疗后和随访时症状严重程度低于安慰剂组。
  • 抗抑郁药未调节DCS效应,且无预设的患者层面或研究层面调节因素与结局相关。

临床怎么用

  • DCS可作为暴露型CBT的增强策略,但效应较小,需权衡获益。
  • 合并使用抗抑郁药不影响DCS增强效应,无需因抗抑郁药使用而调整DCS策略。
  • 目前尚无明确患者或治疗特征可预测DCS应答,需个体化评估。

局限性

  • 未获取全部 eligible 试验的个体数据(21/22项试验,1047/1073例参与者)。
  • 未识别出与DCS应答相关的患者或治疗特征,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether and under which conditions D-cycloserine (DCS) augments the effects of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders is unclear. OBJECTIVE: To clarify whether DCS is superior to placebo in augmenting the effects of cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders and to evaluate whether antidepressants interact with DCS and the effect of potential moderating variables. DATA SOURCES: PubMed, EMBASE, and PsycINFO were searched from inception to February 10, 2016. Reference lists of previous reviews and meta-analyses and reports of randomized clinical trials were also checked. STUDY SELECTION: Studies were eligible for inclusion if they were (1) double-blind randomized clinical trials of DCS as an augmentation strategy for exposure-based cognitive behavior therapy and (2) conducted in humans diagnosed as having specific phobia, social anxiety disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, or posttraumatic stress disorder. DATA EXTRACTION AND SYNTHESIS: Raw data were obtained from the authors and quality controlled. Data were ranked to ensure a consistent metric across studies (score range, 0-100). We used a 3-level multilevel model nesting repeated measures of outcomes within participants, who were nested within studies. RESULTS: Individual participant data were obtained for 21 of 22 eligible trials, representing 1047 of 1073 eligible participants. When controlling for antidepressant use, participants receiving DCS showed greater improvement from pretreatment to posttreatment (mean difference, -3.62; 95% CI, -0.81 to -6.43; P = .01; d = -0.25) but not from pretreatment to midtreatment (mean difference, -1.66; 95% CI, -4.92 to 1.60; P = .32; d = -0.14) or from pretreatment to follow-up (mean difference, -2.98, 95% CI, -5.99 to 0.03; P = .05; d = -0.19). Additional analyses showed that participants assigned to DCS were associated with lower symptom severity than those assigned to placebo at posttreatment and at follow-up. Antidepressants did not moderate the effects of DCS. None of the prespecified patient-level or study-level moderators was associated with outcomes. CONCLUSIONS AND RELEVANCE: D-cycloserine is associated with a small augmentation effect on exposure-based therapy. This effect is not moderated by the concurrent use of antidepressants. Further research is needed to identify patient and/or therapy characteristics associated with DCS response.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Mataix-Cols D, Fernández de la Cruz L, Monzani B, et al. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry. 2017. PMID: 28122091. doi:10.1001/jamapsychiatry.2016.3955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。